Drugs / IONIS-FB-LRx
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT04014335 | Dec 2019 → Feb 2024 | IgA glomerulonephritis | Ionis Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 2 | NCT03815825 | Mar 2019 → Apr 2024 | diffuse secondary choroid atrophy, macular degeneration | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03446144 | Mar → Oct 2018 | age-related macular degeneration, diffuse secondary choroid atrophy | Ionis Pharmaceuticals, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT05797610 | Aug 2023 → Aug 2026 overdue | IgA glomerulonephritis | Hoffmann-La Roche | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-11-07 | Ionis Pharmaceuticals | Results Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022 ionis.com ↗
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a Phase 2 clinical study of IONIS-FB-LRx in patients with immunoglobulin A nephropathy (IgAN). |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-23 | Hoffmann-La Roche | Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN) roche.com ↗ |
| 2026-09-22 | Genentech, Inc. | Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN) gene.com ↗ |
| 2022-11-07 | Ionis Pharmaceuticals | Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022 ionis.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IONIS-FB-Lrx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03446144 ↗ |
| Known as | RO7434656 | “Patients received sefaxersen 70 mg (RO7434656) subcutaneously monthly for 24 weeks followed by voluntary treatment extension.” PMID 41443406 ↗ Dec 20251“Sefaxersen (RO7434656) will be administered as SC injection per schedule as specified.” NCT05797610 ↗ |
| Known as | sefaxersen | “Patients received sefaxersen 70 mg (RO7434656) subcutaneously monthly for 24 weeks followed by voluntary treatment extension.” PMID 41443406 ↗ Dec 2025 |
| Action | Inhibit | “an Antisense Inhibitor of Complement Factor B” NCT03446144 ↗ |
| Modality | Antisense oligonucleotide | “an Antisense Inhibitor of Complement Factor B” NCT03446144 ↗ |
| Route | Subcutaneous | “administered subcutaneously every 4 weeks” NCT03815825 ↗ |
| Target | CFB | “complement factor B messenger ribonucleic acid (CFB mRNA)” NCT04014335 ↗ |